PriceTargets.com logo

Immunovant - IMVT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $28.78
  • Forecasted Upside: 25.61%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$22.91 As of 12/4/2025 05:00 PM ET
▲ +0.2 (0.88%)

This chart shows the closing price for IMVT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immunovant Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMVT

Analyst Price Target is $28.78
▲ +25.61% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $28.78, with a high forecast of $45.00 and a low forecast of $16.00. The average price target represents a 25.61% upside from the last price of $22.91.

This chart shows the closing price for IMVT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Immunovant. This rating has held steady since April 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/14/2025Truist FinancialInitiated CoverageHold$16.00
10/14/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/30/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$37.00 ➝ $33.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$35.00
8/12/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$40.00 ➝ $37.00
8/12/2025Bank of AmericaLower TargetBuy ➝ Buy$33.00 ➝ $30.00
8/11/2025CitigroupReiterated RatingBuy ➝ Buy
7/28/2025UBS GroupBoost TargetNeutral ➝ Neutral$17.00 ➝ $18.00
7/10/2025The Goldman Sachs GroupUpgradeHold$18.00
4/22/2025UBS GroupReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00
3/20/2025GuggenheimReiterated RatingBuy ➝ Buy
3/20/2025Bank of AmericaLower TargetBuy ➝ Buy$38.00 ➝ $33.00
3/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
3/10/2025GuggenheimReiterated RatingBuy ➝ Buy
3/4/2025Cantor FitzgeraldUpgradeStrong-Buy
3/3/2025Jefferies Financial GroupInitiated CoverageHold$20.00
3/2/2025Jefferies Financial GroupReiterated RatingMixed ➝ Mixed
2/10/2025GuggenheimLower TargetBuy ➝ Buy$46.00 ➝ $44.00
2/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
1/30/2025Cantor FitzgeraldUpgradeStrong-Buy
1/15/2025Bank of AmericaLower TargetBuy ➝ Buy$48.00 ➝ $45.00
1/3/2025Wolfe ResearchDowngradeOutperform ➝ Peer Perform
12/19/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$47.00 ➝ $45.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
10/10/2024Raymond James FinancialReiterated RatingOutperform$36.00
10/9/2024OppenheimerBoost TargetOutperform ➝ Outperform$47.00 ➝ $53.00
9/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
9/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/13/2024UBS GroupLower TargetBuy ➝ Buy$42.00 ➝ $41.00
8/8/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$51.00 ➝ $46.00
8/7/2024Cantor FitzgeraldReiterated RatingOverweight
6/18/2024Cantor FitzgeraldReiterated RatingOverweight
6/3/2024OppenheimerLower TargetOutperform ➝ Outperform$50.00 ➝ $46.00
5/30/2024Cantor FitzgeraldReiterated RatingOverweight
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
3/28/2024OppenheimerInitiated CoverageOutperform$50.00
3/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$48.00
3/13/2024The Goldman Sachs GroupInitiated CoverageBuy$50.00
2/20/2024JPMorgan Chase & Co.Initiated CoverageOverweight$51.00
2/15/2024Wolfe ResearchInitiated CoverageOutperform$55.00
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
12/21/2023Bank of AmericaBoost TargetBuy ➝ Buy$49.00 ➝ $51.00
12/21/2023HC WainwrightBoost TargetBuy ➝ Buy$47.00 ➝ $51.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$50.00
12/1/2023UBS GroupBoost TargetBuy ➝ Buy$55.00 ➝ $56.00
11/15/2023Truist FinancialBoost TargetBuy ➝ Buy$30.00 ➝ $48.00
10/24/2023Piper SandlerBoost TargetOverweight ➝ Overweight$28.00 ➝ $57.00
10/24/2023HC WainwrightBoost TargetBuy ➝ Buy$29.00 ➝ $47.00
10/16/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$30.00 ➝ $45.00
10/13/2023UBS GroupUpgradeNeutral ➝ Buy$18.00 ➝ $55.00
10/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00
9/27/2023GuggenheimBoost Target$32.00 ➝ $48.00
9/27/2023CitigroupBoost TargetBuy ➝ Buy$33.00 ➝ $50.00
9/27/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$33.00 ➝ $48.00
9/26/2023Truist FinancialReiterated RatingBuy ➝ Buy$30.00
9/26/2023Raymond James FinancialUpgradeMarket Perform ➝ Outperform$40.00
9/22/2023GuggenheimReiterated RatingBuy ➝ Buy$32.00
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00
8/16/2023Truist FinancialReiterated RatingBuy ➝ Buy$30.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$29.00
8/11/2023CitigroupBoost TargetBuy ➝ Buy$28.00 ➝ $33.00
7/24/2023Wells Fargo & CompanyBoost TargetOverweight$27.00 ➝ $33.00
7/18/2023Stifel NicolausBoost TargetBuy$28.00 ➝ $34.00
7/18/2023HC WainwrightBoost TargetBuy$27.00 ➝ $29.00
7/10/2023Chardan CapitalReiterated RatingBuy
5/23/2023Bank of AmericaBoost Target$26.00 ➝ $28.00
5/23/2023GuggenheimBoost Target$30.00 ➝ $32.00
5/23/2023HC WainwrightBoost Target$26.00 ➝ $27.00
5/22/2023Chardan CapitalBoost Target$21.00 ➝ $32.00
5/1/2023Bank of AmericaInitiated CoverageBuy$26.00
4/25/2023CitigroupInitiated CoverageBuy$28.00
3/31/2023Piper SandlerInitiated CoverageOverweight$28.00
3/29/2023Stifel NicolausInitiated CoverageBuy$28.00
3/20/2023HC WainwrightBoost Target$21.00 ➝ $26.00
2/15/2023Cantor FitzgeraldInitiated CoverageOverweight$30.00
2/13/2023GuggenheimUpgradeNeutral ➝ Buy$30.00
2/7/2023HC WainwrightBoost TargetBuy$17.00 ➝ $21.00
2/6/2023Leerink PartnersBoost TargetOutperform$14.00 ➝ $21.00
2/5/2023Chardan CapitalBoost TargetBuy$19.00 ➝ $21.00
1/2/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$10.00 ➝ $27.00
11/17/2022Truist FinancialBoost Target$30.00
11/8/2022Wells Fargo & CompanyBoost TargetEqual Weight$7.00 ➝ $10.00
11/7/2022HC WainwrightBoost TargetBuy$16.00 ➝ $17.00
11/7/2022Chardan CapitalBoost TargetBuy$12.00 ➝ $19.00
11/4/2022Leerink PartnersBoost TargetOutperform$12.00 ➝ $14.00
9/29/2022Chardan CapitalLower TargetBuy$14.00 ➝ $12.00
9/26/2022UBS GroupDowngradeBuy ➝ Neutral$7.00 ➝ $5.00
6/9/2022Robert W. BairdLower Target$6.00
6/9/2022HC WainwrightReiterated RatingBuy$16.00
5/20/2022UBS GroupLower Target$7.00
3/30/2022Chardan CapitalLower Target$20.00 ➝ $14.00
3/29/2022Chardan CapitalReiterated RatingBuy
3/22/2022Chardan CapitalReiterated RatingBuy
2/7/2022HC WainwrightReiterated RatingBuy$16.00
1/5/2022Chardan CapitalLower TargetBuy ➝ Buy$22.00 ➝ $20.00
12/30/2021Truist FinancialReiterated RatingBuy$12.00
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$9.00
11/8/2021HC WainwrightLower TargetBuy$19.00 ➝ $16.00
10/26/2021Truist FinancialLower TargetBuy$24.00 ➝ $12.00
8/13/2021Chardan CapitalLower TargetBuy$55.00 ➝ $22.00
8/10/2021HC WainwrightReiterated RatingBuy$19.00
8/3/2021Robert W. BairdDowngradeOutperform ➝ Neutral$20.00 ➝ $10.00
8/2/2021Credit Suisse GroupDowngradeNeutral ➝ Underperform$12.00 ➝ $7.00
7/7/2021Chardan CapitalReiterated RatingBuy
7/1/2021Chardan CapitalReiterated RatingBuy
6/2/2021Credit Suisse GroupBoost TargetNeutral$12.00 ➝ $26.00
6/2/2021Leerink PartnersLower TargetOutperform$38.00 ➝ $17.00
6/2/2021Robert W. BairdLower TargetOutperform$32.00 ➝ $20.00
6/2/2021HC WainwrightLower TargetBuy$23.00 ➝ $19.00
6/1/2021Raymond James FinancialDowngradeOutperform ➝ Market Perform
6/1/2021GuggenheimDowngradeBuy ➝ Neutral
6/1/2021Stifel NicolausDowngradeBuy ➝ Hold$28.00 ➝ $9.00
5/10/2021HC WainwrightLower TargetBuy$33.00 ➝ $23.00
2/16/2021Stifel NicolausReiterated RatingBuy$28.00
2/3/2021Raymond James FinancialLower TargetOutperform$58.00 ➝ $35.00
2/3/2021Leerink PartnersLower TargetOutperform$52.00 ➝ $38.00
2/3/2021HC WainwrightLower TargetBuy$54.00 ➝ $33.00
2/2/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral
2/2/2021Stifel NicolausLower TargetBuy$54.00 ➝ $33.00
1/13/2021HC WainwrightReiterated RatingBuy$54.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 34 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 26 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 12 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 26 very positive mentions
  • 9 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 10 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 10 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 9 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 9 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $22.91
Low: $22.29
High: $23.31

50 Day Range

MA: $20.79
Low: $16.06
High: $24.82

52 Week Range

Now: $22.91
Low: $12.72
High: $29.49

Volume

1,318,878 shs

Average Volume

1,268,560 shs

Market Capitalization

$4.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunovant?

The following equities research analysts have issued research reports on Immunovant in the last twelve months: Bank of America Corporation, Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Weiss Ratings, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for IMVT.

What is the current price target for Immunovant?

0 Wall Street analysts have set twelve-month price targets for Immunovant in the last year. Their average twelve-month price target is $28.78, suggesting a possible upside of 25.6%. Wells Fargo & Company has the highest price target set, predicting IMVT will reach $45.00 in the next twelve months. Truist Financial Corporation has the lowest price target set, forecasting a price of $16.00 for Immunovant in the next year.
View the latest price targets for IMVT.

What is the current consensus analyst rating for Immunovant?

Immunovant currently has 1 sell rating, 4 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IMVT.

What other companies compete with Immunovant?

Other companies that are similar to Immunovant include Soleno Therapeutics, Revolution Medicines, Roivant Sciences, BridgeBio Pharma and Summit Therapeutics. Learn More about companies similar to Immunovant.

How do I contact Immunovant's investor relations team?

Immunovant's physical mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company's listed phone number is 917-580-3099 and its investor relations email address is [email protected]. The official website for Immunovant is www.immunovant.com. Learn More about contacing Immunovant investor relations.